COSENTYX DRUG MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Regional Analysis

To learn more about this report, request sample copy

North America region is anticipated to dominate the market with 45.7% of the market share in 2024. With a large population suffering from autoimmune disorders including psoriasis and arthritis, Cosentyx has a huge potential patient pool. Most private and public health plans also provide decent coverage for expensive biologic drugs like Cosentyx, thus, ensuring affordability and access for patients. Promising clinical research trials conducted in the U.S. also influence prescribing habits of doctors. With several manufacturing sites located within the country, logistical and supply chain management for Cosentyx is well-streamlined in the region.

The Asia Pacific region is fast becoming an important emerging market for Cosentyx. This can be attributed to rising disease prevalence in developing economies like China and India, owing to changing lifestyles. These nations also have a very large patient pool suffering from various autoimmune conditions. Rising incomes has made expensive biologic treatments potentially viable options for Asian patients as well. However, lack of awareness still remains a critical challenge to be addressed by all stakeholders in the APAC Cosentyx market.